Cara Therapeutics, INC Form 4 insider transactions

Michael S. Wyzga, a director of Tvardi Therapeutics, acquired stock options for 18,441 shares of common stock following the merger with Legacy Tvardi.

Yixin Chen, VP of Chemistry, Manufacturing, and Controls at Tvardi Therapeutics, acquires stock options following a merger.

Director Shaheen Wirk reports changes in beneficial ownership of Tvardi Therapeutics stock following the merger with Cara Therapeutics, including acquisitions of common stock and stock options.

Director Sujal Shah reports acquisition and disposal of stock options in Tvardi Therapeutics following a merger, according to a Form 4 filing.

Jeffrey Leroy Larson, SVP of Research & Development at Tvardi Therapeutics, acquired stock options as a result of the merger with Legacy Tvardi.

Avi Daniel Conn, CFO of Tvardi Therapeutics, reports acquisition of stock options following the merger with Legacy Tvardi.

Imran Nizamudin Alibhai, CEO of Tvardi Therapeutics, reports acquisition of stock options following the merger with Legacy Tvardi.

Cara Therapeutics provides supplemental disclosures to its proxy statement/prospectus related to the proposed merger with Tvardi Therapeutics in response to stockholder demands and lawsuits alleging materially false and misleading statements.

Christopher Posner, CEO of Cara Therapeutics, sold 583 shares of common stock on February 28, 2025, to cover tax obligations related to vesting restricted stock units.

Scott Terrillion, a Cara Therapeutics officer, sold 163 shares of common stock on February 28, 2025, to cover tax obligations related to vesting restricted stock units.

Christopher Posner, CEO of Cara Therapeutics, sold 372 shares of common stock on February 4, 2025, to cover tax obligations related to vesting restricted stock units.

Cara Therapeutics and Tvardi Therapeutics have agreed to merge, creating a combined entity focused on advancing Tvardi's STAT3-targeting therapies for fibrosis-driven diseases.

Cara Therapeutics has regained compliance with Nasdaq's minimum bid price requirement but still needs to address its stockholders' equity deficiency.

Cara Therapeutics enacted a 1-for-12 reverse stock split and reduced its authorized shares on December 30, 2024, to comply with Nasdaq requirements and facilitate a proposed acquisition.

Cara Therapeutics and Tvardi Therapeutics have announced a merger agreement, with the combined company focusing on advancing Tvardi's STAT3-targeting therapies for fibrosis-driven diseases.

Cara Therapeutics and Tvardi Therapeutics have agreed to merge, forming a Nasdaq-listed company focused on developing novel treatments targeting STAT3 for fibrosis-driven diseases.

Christopher Posner, CEO of Cara Therapeutics, sold 3,668 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Christopher Posner, CEO of Cara Therapeutics, sold 4,149 shares of common stock at $0.35 per share to cover tax withholding obligations related to vesting restricted stock units.

Director Helen M. Boudreau acquired 150,647 restricted stock units and 195,000 stock options in Cara Therapeutics, Inc. on June 4, 2024.

Director Lisa von Moltke reported the acquisition of stock and option awards from Cara Therapeutics, Inc.

Director Jeffrey L. Ives receives stock options and restricted stock units from Cara Therapeutics, Inc.

Director Susan Shiff received stock options and restricted stock units from Cara Therapeutics, according to a recent SEC filing.

Director Martin Vogelbaum acquired stock options and restricted stock units in Cara Therapeutics, according to a recent SEC filing.

Christopher Posner, CEO of Cara Therapeutics, sold 3,936 shares of common stock to cover tax obligations related to vesting restricted stock units.

Joana Goncalves, Chief Medical Officer of Cara Therapeutics, sold 2,753 shares of common stock on April 5, 2024, to cover tax obligations related to vesting restricted stock units.

Scott Terrillion, a Cara Therapeutics officer, sold 2,753 shares of common stock to cover tax obligations related to vesting restricted stock units.

Scott Terrillion, a Cara Therapeutics officer, sold 3,293 shares of common stock on February 29, 2024, to cover tax obligations related to vesting restricted stock units.

Christopher Posner, CEO of Cara Therapeutics, sold 5,834 shares of common stock on February 29, 2024, to cover tax obligations related to vesting restricted stock units.

Joana Goncalves, Chief Medical Officer of Cara Therapeutics, sold 3,293 shares of common stock to cover tax withholding obligations.